Epram 5 mg (Escitalopram Oxalate)

Adult administration

The safety of doses exceeding 20 mg per day has not been established. This medication is administered once daily, in the morning or evening, regardless of meals. Major depressive disorder: The usual dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. If increasing the dose of this medication to 20 mg, increase it at intervals of at least 1 week. Antidepressant effects generally take 2-4 weeks to appear. Even after symptoms have resolved, medication treatment for at least 6 months is needed to ensure the therapeutic effect. Panic disorder with or without agoraphobia: It is recommended to start with 5 mg once daily for 1 week and then increase the dose to 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. The maximum effect appears after approximately 3 months. The safety and efficacy of long-term use of this medication for more than 10 weeks in the treatment of panic disorder have not been systematically studied. The physician should periodically reassess each patient to determine the need for continued treatment. Social anxiety disorder: The usual dose is 10 mg once daily. Symptom improvement generally takes 2-4 weeks. Thereafter, depending on the patient's response, the dose may be reduced to 5 mg per day or increased to a maximum of 20 mg per day. Social anxiety disorder is a chronic condition, and continued treatment for 12 weeks is recommended to ensure the therapeutic effect. Long-term treatment of responding patients has been studied for 6 months, and should be considered on an individual basis to prevent relapse. The usefulness of long-term treatment should be reassessed regularly. Generalized anxiety disorder: The initial dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day after at least 1 week of treatment. A long-term study was conducted in patients who responded to 12 weeks of open-label treatment, with 20 mg per day administered for at least 6 months. The physician should regularly reassess the usefulness of long-term treatment with this medication for each patient. Obsessive-compulsive disorder: The usual dose is 10 mg once daily. Depending on the patient's response, the dose may be increased to a maximum of 20 mg per day. A long-term study was conducted in patients who responded to 16 weeks of open-label treatment, with 10 mg or 20 mg per day administered for at least 24 weeks. Obsessive-compulsive disorder is a chronic condition, and treatment should continue for a sufficient period to ensure recovery from symptoms. If this medication is used long-term, the benefit and dose should be reassessed regularly for each patient. No dose adjustment is necessary in patients with mild or moderate renal impairment. Caution is advised in patients with severe renal impairment (CLCR < 30㎖/min). An initial dose of 5 mg per day for the first 2 weeks is recommended. Depending on the patient's response, the dose may be increased to 10 mg per day. When discontinuing this medication, the dose should be reduced gradually over at least 1-2 weeks to avoid the possibility of withdrawal symptoms. When discontinuing an MAO inhibitor used to treat psychiatric disorders and starting treatment with this medication, an interval of at least 14 days should be allowed. Conversely, when starting an MAO inhibitor to treat psychiatric disorders, at least 14 days should have elapsed after discontinuing this medication. Patients should be monitored for symptoms of serotonin syndrome for 2 weeks after administration of linezolid or intravenous methylene blue, or until 24 hours after the last dose, whichever comes first. Treatment with this medication may be resumed 24 hours after the last dose of linezolid or intravenous methylene blue.

This medication is an antidepressant used to treat psychiatric disorders such as major depression. This medication may increase the risk of suicidal thoughts or behaviors, especially in children, adolescents, and young adults aged 18 to 24, so careful review and close monitoring are needed when administering to patients in this age group. This medication should not be taken with certain other drugs, especially monoamine oxidase inhibitors (MAOIs), pimozide, and medications that prolong the QT interval, as it can pose risks. Patients with glaucoma or a history of glaucoma must be cautious as this medication may dilate the pupils and raise intraocular pressure. Symptoms such as anxiety, agitation, and insomnia may occur initially after administration, typically improving within 2 weeks, but if severe, consultation with a physician is necessary. This medication can lower sodium levels in the blood, requiring caution in elderly patients or those with liver disease or at risk for hyponatremia. Additionally, there may be an increased risk of bleeding, so caution is needed when taking anticoagulants or medications that affect platelet function. Abruptly stopping this medication can lead to withdrawal symptoms such as dizziness, anxiety, and sleep disturbances, so it is essential to gradually taper the dosage according to a physician's instructions. Patients with heart disease or a history of prolonged QT interval may need an electrocardiogram before and during treatment with this medication. Pregnant or breastfeeding women should have thorough consultations with their physician regarding the administration of this medication, especially during late pregnancy, as it could affect the newborn. Elderly patients generally start at a lower dose, requiring careful observation for any adverse reactions during treatment. This medication is reported not to significantly affect driving or machine operation abilities; however, individual variability does exist, so caution is advised. In cases of overdose, symptoms may arise in the central nervous system, gastrointestinal tract, or cardiovascular system, so immediate contact with a medical institution is necessary to receive appropriate treatment. Finally, this medication is not recommended for use in children and adolescents due to insufficient evidence of safety and efficacy.

Thrombocytopenia, anaphylactic reaction, inappropriate secretion of antidiuretic hormone, hyperprolactinemia, decreased appetite, increased appetite, weight gain, weight loss, hyponatremia, anorexia, anxiety, restlessness, abnormal dreams, decreased libido, sexual dysfunction, bruxism, agitation, neuroticism, panic attack, confusion, aggression, depersonalization, hallucination, mania, suicidal ideation, suicidal behavior, insomnia, drowsiness, dizziness, paresthesia, tremors, taste disorders, sleep disturbances, syncope, serotonin syndrome, movement disorders, dyskinesia, convulsions, psychomotor agitation, akathisia, mydriasis, visual impairment, tinnitus, tachycardia, bradycardia, prolonged QT interval on ECG, polymorphic ventricular tachycardia, orthostatic hypotension, sinusitis, yawning, nosebleed, nausea, diarrhea, constipation, vomiting, dry mouth, gastrointestinal bleeding, hepatitis, abnormal liver function tests, increased sweating, urticaria, hair loss, rash, itching, petechiae, angioedema, arthralgia, myalgia, rhabdomyolysis, urinary retention, ejaculation disorder, erectile dysfunction, uterine bleeding, menorrhagia, galactorrhea, postpartum hemorrhage, priapism, fatigue, fever, edema, headache, xerostomia, abdominal pain, dyspepsia, gastroenteritis, sensory disturbances, cough, asthma, dyspnea, fracture, palpitations, hypertension, paralysis, extrapyramidal disorder, migraine, chest pain, frequent urination, tremors, dry mouth, sedation, heartburn, anxiety, visual hallucinations, sexual dysfunction, decreased libido, anorexia

This medication should be stored in a tightly closed container to prevent air and moisture ingress. It is advisable to keep it at room temperature between 1 to 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

For domestic use - 30 tablets/bottle, For domestic use - 100 tablets/bottle